Treatment of resected brain tumour beds using nanoparticle enhanced radiotherapy

尽管在一些常见癌症的治疗方面取得了很大进展，但仍有许多癌症几十年来几乎没有改善。其中之一是侵袭性脑瘤，它的中位生存期为14.6个月--这一数字在过去40年里没有改善。目前支持最好的治疗是手术，尽可能多地切除肿瘤，然后是放射治疗和化疗。癌症在这一区域有规律地复发，并且进展迅速。将开发一种独特的纳米颗粒水凝胶，它将在残留癌症区域释放纳米颗粒。这些纳米粒子提高了放射治疗的效果。这个项目将把Xarion Healthcare Ltd(一家开发放射增强纳米颗粒的中小企业)和Medicines Discovery Catapult(MDC)(一家专门从事临床前开发和成像的CRO)结合在一起，开发一种独特的产品，该产品将增强手术后放射治疗侵袭性脑瘤的效果，并减少癌症复发的可能性。该项目将使Xarion能够将该产品推向临床试验。鉴于对这种毁灭性疾病的新治疗方法的关键临床需求，Xarion预计新方法的推出和采用将是迅速的。

Although great progress has been made in the treatment of some common cancers there remain many where there has been little improvement over decades. One of these is aggressive brain tumours, which have a median survival time of 14.6 months -- a figure that has not improved over the last four decades.The current best-supported care is surgery, which removes as much of the tumour as possible, followed by radiotherapy and chemotherapy. Cancer regularly reappears in this region and progresses rapidly.A unique nanoparticle loaded hydrogel will be developed which will release nanoparticles in areas of residual cancer. These nanoparticles improve the effectiveness of radiotherapy. This project will bring together Xerion Healthcare Ltd, a SME developing radiotherapy enhancing nanoparticles, and the Medicines Discovery Catapult (MDC), a CRO that specialises in pre-clinical development and imaging to develop a unique product that will enhance the effect of post-surgical radiotherapy on aggressive brain tumours and reduce the prospects of cancer regrowth.This project will enable Xerion to take the product forward to clinical trials. Given the critical clinical need for new treatments for this devastating disease, Xerion expects the rollout and uptake to be rapid.